These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 26144315)

  • 1. PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.
    Zou HY; Friboulet L; Kodack DP; Engstrom LD; Li Q; West M; Tang RW; Wang H; Tsaparikos K; Wang J; Timofeevski S; Katayama R; Dinh DM; Lam H; Lam JL; Yamazaki S; Hu W; Patel B; Bezwada D; Frias RL; Lifshits E; Mahmood S; Gainor JF; Affolter T; Lappin PB; Gukasyan H; Lee N; Deng S; Jain RK; Johnson TW; Shaw AT; Fantin VR; Smeal T
    Cancer Cell; 2015 Jul; 28(1):70-81. PubMed ID: 26144315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
    Infarinato NR; Park JH; Krytska K; Ryles HT; Sano R; Szigety KM; Li Y; Zou HY; Lee NV; Smeal T; Lemmon MA; Mossé YP
    Cancer Discov; 2016 Jan; 6(1):96-107. PubMed ID: 26554404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
    Zou HY; Li Q; Engstrom LD; West M; Appleman V; Wong KA; McTigue M; Deng YL; Liu W; Brooun A; Timofeevski S; McDonnell SR; Jiang P; Falk MD; Lappin PB; Affolter T; Nichols T; Hu W; Lam J; Johnson TW; Smeal T; Charest A; Fantin VR
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3493-8. PubMed ID: 25733882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.
    Johnson TW; Richardson PF; Bailey S; Brooun A; Burke BJ; Collins MR; Cui JJ; Deal JG; Deng YL; Dinh D; Engstrom LD; He M; Hoffman J; Hoffman RL; Huang Q; Kania RS; Kath JC; Lam H; Lam JL; Le PT; Lingardo L; Liu W; McTigue M; Palmer CL; Sach NW; Smeal T; Smith GL; Stewart AE; Timofeevski S; Zhu H; Zhu J; Zou HY; Edwards MP
    J Med Chem; 2014 Jun; 57(11):4720-44. PubMed ID: 24819116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
    Sakamoto H; Tsukaguchi T; Hiroshima S; Kodama T; Kobayashi T; Fukami TA; Oikawa N; Tsukuda T; Ishii N; Aoki Y
    Cancer Cell; 2011 May; 19(5):679-90. PubMed ID: 21575866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.
    Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
    J Pharmacol Exp Ther; 2014 Oct; 351(1):67-76. PubMed ID: 25073473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives.
    Guo M; Zuo D; Zhang J; Xing L; Gou W; Jiang F; Jiang N; Zhang D; Zhai X
    Eur J Med Chem; 2018 Oct; 158():322-333. PubMed ID: 30223120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.
    Guan J; Tucker ER; Wan H; Chand D; Danielson LS; Ruuth K; El Wakil A; Witek B; Jamin Y; Umapathy G; Robinson SP; Johnson TW; Smeal T; Martinsson T; Chesler L; Palmer RH; Hallberg B
    Dis Model Mech; 2016 Sep; 9(9):941-52. PubMed ID: 27483357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lorlatinib Is Active in Drug-Resistant NSCLC.
    Cancer Discov; 2016 Aug; 6(8):OF1. PubMed ID: 27401797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors.
    Xia ZJ; Ji YC; Sun DQ; Peng X; Gao YL; Fang YF; Zhao XD; Wang WB; Ding J; Geng MY; Ai J
    Acta Pharmacol Sin; 2021 Jun; 42(6):998-1004. PubMed ID: 32918045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First macrocyclic 3
    Basit S; Ashraf Z; Lee K; Latif M
    Eur J Med Chem; 2017 Jul; 134():348-356. PubMed ID: 28431340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
    Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
    Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.
    Mologni L; Ceccon M; Pirola A; Chiriano G; Piazza R; Scapozza L; Gambacorti-Passerini C
    Oncotarget; 2015 Mar; 6(8):5720-34. PubMed ID: 25749034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting ALK: The Ten Lives of a Tumor.
    Versteeg R; George RE
    Cancer Discov; 2016 Jan; 6(1):20-1. PubMed ID: 26747894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
    Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
    Kodama T; Tsukaguchi T; Yoshida M; Kondoh O; Sakamoto H
    Cancer Lett; 2014 Sep; 351(2):215-21. PubMed ID: 24887559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
    Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
    J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
    Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
    Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
    Drug Metab Dispos; 2015 Jan; 43(1):54-62. PubMed ID: 25349124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.
    Nanjo S; Nakagawa T; Takeuchi S; Kita K; Fukuda K; Nakada M; Uehara H; Nishihara H; Hara E; Uramoto H; Tanaka F; Yano S
    Cancer Sci; 2015 Mar; 106(3):244-52. PubMed ID: 25581823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.